Literature DB >> 29538243

Morphology and Clinical Relevance of Vertebral Endplate Changes Following Limited Lumbar Discectomy With or Without Bone-anchored Annular Closure.

Adisa Kuršumović1, Jenny C Kienzler2, Gerrit J Bouma3, Richard Bostelmann4, Michael Heggeness5, Claudius Thomé6, Larry E Miller7, Martin Barth8.   

Abstract

STUDY
DESIGN: Post hoc analysis of a randomized controlled trial.
OBJECTIVE: To characterize the morphology and clinical relevance of vertebral endplate changes (VEPC) following limited lumbar discectomy with or without implantation of a bone-anchored annular closure device (ACD). SUMMARY OF BACKGROUND DATA: Implantation of an ACD following limited lumbar discectomy has shown promise in reducing the risk of recurrent herniation in patients with large annular defects. However, the interaction between the ACD and the lumbar endplate over time is not well understood.
METHODS: Patients undergoing limited lumbar discectomy with large postsurgical annular defects were randomized intraoperatively to receive additional ACD implantation or limited lumbar discectomy only (Controls). VEPC morphology, area, and volume were assessed with low-dose computed tomography preoperatively and at 1 and 2 years follow-up.
RESULTS: Of 554 randomized patients, the as-treated population consisted of 550 patients (267 ACD, 283 Controls). VEPC were preoperatively identified in 18% of patients in the ACD group and in 15% of Controls. At 2 years, VEPC frequency increased to 85% with ACD and 33% in Controls. Device- or procedure-related serious adverse event (8% vs. 17%, P = 0.001) and secondary surgical intervention (5% vs. 13%, P < 0.001) favored the ACD group over Controls. In the ACD group, clinical outcomes were comparable in patients with and without VEPC at 2 years follow-up. In the Control group, patients with VEPC at 2 years had higher risk of symptomatic reherniation versus patients without VEPC (35% vs. 19%, P < 0.01) CONCLUSION.: In patients with large annular defects following limited lumbar discectomy, additional implantation with a bone-anchored ACD reduces risk of postoperative complications despite a greater frequency of VEPC. VEPC were associated with higher risk of symptomatic reherniation in patients treated with limited lumbar discectomy, but not in those who received additional ACD implantation. LEVEL OF EVIDENCE: 2.

Entities:  

Mesh:

Year:  2018        PMID: 29538243     DOI: 10.1097/BRS.0000000000002632

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  5 in total

1.  Predictors of Treatment Success Following Limited Discectomy With Annular Closure for Lumbar Disc Herniation.

Authors:  Aleksandr V Krutko; Abdugafur J Sanginov; Evgenii S Baykov
Journal:  Int J Spine Surg       Date:  2020-02-29

2.  Effectiveness of an annular closure device in a "real-world" population: stratification of registry data using screening criteria from a randomized controlled trial.

Authors:  Adisa Kuršumović; Stefan A Rath
Journal:  Med Devices (Auckl)       Date:  2018-06-07

3.  Three-year results from a randomized trial of lumbar discectomy with annulus fibrosus occlusion in patients at high risk for reherniation.

Authors:  Jenny C Kienzler; Peter Douglas Klassen; Larry E Miller; Richard Assaker; Volkmar Heidecke; Susanne Fröhlich; Claudius Thomé
Journal:  Acta Neurochir (Wien)       Date:  2019-05-15       Impact factor: 2.216

4.  Incidence and clinical impact of vertebral endplate changes after limited lumbar microdiscectomy and implantation of a bone-anchored annular closure device.

Authors:  Jenny C Kienzler; Sofia Rey; Oliver Wetzel; Hermien Atassi; Sabrina Bäbler; Felice Burn; Javier Fandino
Journal:  BMC Surg       Date:  2021-01-06       Impact factor: 2.102

5.  Clinical Implications of Vertebral Endplate Disruptions After Lumbar Discectomy: 3-Year Results from a Randomized Trial of a Bone-Anchored Annular Closure Device.

Authors:  Adisa Kuršumović; Gerrit Joan Bouma; Larry E Miller; Richard Assaker; Erik Van de Kelft; Robert Hes; Jenny C Kienzler
Journal:  J Pain Res       Date:  2020-03-31       Impact factor: 3.133

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.